Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
IPO Year: 2013
Exchange: NASDAQ
Website: veracyte.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $45.00 | Buy | Craig Hallum |
| 12/5/2024 | $38.00 → $37.00 | Buy → Neutral | Goldman |
| 11/15/2024 | $50.00 | Outperform | Wolfe Research |
| 10/16/2024 | $43.00 | Buy | UBS |
| 10/10/2024 | $40.00 | Buy | Guggenheim |
| 2/23/2024 | $30.00 → $33.00 | Buy | Needham |
| 1/18/2023 | Outperform → Mkt Perform | Raymond James | |
| 1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
| 3/2/2022 | $52.00 → $44.00 | Overweight | Stephens & Co. |
| 3/1/2022 | $62.00 → $34.00 | Outperform | Raymond James |
Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a
Veracyte, Inc. (NASDAQ:VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has spread beyond the primary tumor. The Decipher Prostate test, already widely used for patients with localized disease, is now the only gene expression test available and covered by Medicare to inform treatment decisions for patients across the full continuum of prostate cancer risk. Veracyte has begun making the Decipher Prostate Metastatic test available to select clinical sites through an early access program and will begin taking orders for the test more broadly in June 2025. Prostate cancer i
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2025, the annual meeting of the American Urological Association, taking place April 26-29 in Las Vegas. Study findings to be presented include new data from the use of the Decipher tests in clinical trials as well as insights into these cancers' underlying biology, which researchers derived through use of the whole-transcriptome-based Decipher GRID (Genomic Resource for Intelligent Discovery) research tool. "Our whole-transcriptome approach to Decipher testing provides us with a rich
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate Genomic Classifier are available in a new specialized database that the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) Program just released. This database will enable eligible researchers to evaluate Decipher Prostate test results in the context of real-world patient outcomes, prostate cancer characteristics, treatment protocols, demographics and other factors. "We are excited about the numerous opportunities that our collaboration with the NCI SEER Program will enable for prostate cancer researchers and, ultimately
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter of 2025 after the close of market on Wednesday, May 7, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/5r4msrbq. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/
Findings from TOMBOLA Trial Were Presented at EAU25 Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer in patients treated for muscle-invasive bladder cancer (MIBC) with more accuracy than ddPCR-based blood testing and earlier compared to standard imaging. The findings, from the large, independent, multicenter, interventional TOMBOLA trial (NCT04138628), were shared in an oral presentation at the 40th Annual European Association of Urology Congress (EAU25) in Madrid by Iver Nordentoft, Ph.D., Aarhus University (Abstract A0162: "C
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that multiple abstracts will be presented at the 40th Annual European Association of Urology Congress (EAU25) demonstrating the clinical performance and utility of its Decipher tests in prostate and bladder cancer. Additionally, independent performance data supporting the company's minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer will be unveiled from a large, multicenter trial. The EAU25 meeting is taking place March 21-24 at IFEMA Madrid in Spain. "These new data reinforce the impact our Decipher tests are having on patient care in prostate and bladder cancers and how our
Grew fourth quarter total revenue to $118.6 million, an increase of 21% Grew fourth quarter testing revenue to $112.2 million, an increase of 24% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. "I'm incredibly proud of what our team accomplished in 2024," said Marc Stapley, Veracyte's chief executive officer. "We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant opportunities for Decipher and Afirma to impact
Veracyte, Inc. (NASDAQ:VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 46th Annual Institutional Investors Conference – Orlando, FL Presentation on March 5th at 9:50 a.m. Eastern Time Leerink Partners Global Healthcare Conference – Miami, FL Fireside Chat on March 11th at 8:40 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast. About Veracyte Veracyte (NASDAQ:VCYT) is a global diagnostics
Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer. Presented findings also show that the company's Decipher GRID (Genomic Resource for Intelligent Discovery) research tool is enabling new data-based insights that in the future may help further advance persona
10-Q - VERACYTE, INC. (0001384101) (Filer)
8-K - VERACYTE, INC. (0001384101) (Filer)
SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)
SCHEDULE 13G - VERACYTE, INC. (0001384101) (Subject)
DEFA14A - VERACYTE, INC. (0001384101) (Filer)
DEF 14A - VERACYTE, INC. (0001384101) (Filer)
10-K - VERACYTE, INC. (0001384101) (Filer)
8-K - VERACYTE, INC. (0001384101) (Filer)
144 - VERACYTE, INC. (0001384101) (Subject)
144 - VERACYTE, INC. (0001384101) (Subject)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter of 2025 after the close of market on Wednesday, May 7, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/5r4msrbq. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/
Grew fourth quarter total revenue to $118.6 million, an increase of 21% Grew fourth quarter testing revenue to $112.2 million, an increase of 24% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. "I'm incredibly proud of what our team accomplished in 2024," said Marc Stapley, Veracyte's chief executive officer. "We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant opportunities for Decipher and Afirma to impact
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2024 after the close of market on Monday, February 24, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/8em9yd38. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://invest
Grew total revenue to $115.9 million, an increase of 29% Grew testing revenue to $109.5 million, an increase of 34% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the third quarter ended September 30, 2024. "The strong momentum across our testing business continued during the third quarter as we delivered record revenue along with profitability and cash generation," said Marc Stapley, Veracyte's chief executive officer. "Looking ahead, we see tremendous opportunities for further market penetration for both Decipher and Afirma, to serve even more patients and their physicians. We also remain excited about our focused p
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/kzh3s376. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte
Grew total revenue to $114.4 million, an increase of 27% Grew testing revenue by 31% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the second quarter ended June 30, 2024. "Our exceptional second quarter results are a testament to the strength and robustness of Decipher and Afirma," said Marc Stapley, Veracyte's chief executive officer. "With both tests clearly gaining share in their respective markets and plenty of headroom for durable future expansion, our confidence in their long-term prospects continues to grow. Meanwhile, our positive cash generation and class-leading profitability profile are fueling a portf
Veracyte, Inc. (NASDAQ:VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, August 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/p5tuszv4. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations. The conferen
Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the first quarter ended March 31, 2024. "We had a strong start to 2024, driven by robust growth from our market-leading Decipher Prostate and Afirma tests. We executed upon our strategies to further penetrate these markets by expanding our clinical evidence, and, for Decipher, securing enhanced status in guidelines while also achieving a key commercial reimbursement milestone," said Marc Stapley, Veracyte's chief executive officer. "We also expanded our capabilities into minimal residu
Veracyte, Inc. (NASDAQ:VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/6m9ec99y. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations. The conference c
SC 13G - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac
Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a
Veracyte, Inc. (NASDAQ:VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately. "We are thrilled to welcome Eliav Barr to our board," said Marc Stapley, Veracyte's chief executive officer. "Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology." Dr. Barr has built his distinguished career at Merck Research Labo
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. "We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are very fortunate to benef
Veracyte, Inc. (NASDAQ:VCYT), a global diagnostics company, today announced that it has appointed Annie McGuire as senior vice president and general counsel, effective immediately. Ms. McGuire will oversee all aspects of the company's legal functions and will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220228005304/en/Veracyte Appoints Annie McGuire as General Counsel (Photo: Business Wire) "We are delighted to welcome Annie to Veracyte," said Mr. Stapley. "She brings with her significant experience in Fortune 100 and other healthcare companies. Her proven leadership
Veracyte, Inc. (NASDAQ:VCYT), a global diagnostics company, today announced that it has appointed Jonathan Wygant as chief accounting officer, effective immediately. Mr. Wygant will oversee all aspects of the company's global accounting operations, financial reporting and tax functions. He will report to Rebecca Chambers, Veracyte's chief financial officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220222005393/en/Veracyte Appoints Jonathan Wygant as Chief Accounting Officer (Photo: Business Wire) "We are thrilled to welcome Jonathan to Veracyte," said Ms. Chambers. "He brings a depth of expertise and experience leading acco
Veracyte, Inc. (NASDAQ:VCYT), a global genomic diagnostics company, today announced that it has appointed Joshua Klopper, M.D., as medical director of Endocrinology. Dr. Klopper is a nationally recognized endocrinologist who specializes in the evaluation and management of thyroid nodules and thyroid cancer. He joins Veracyte today, reporting to Richard T. Kloos, M.D., Veracyte's executive medical director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005316/en/Joshua Klopper, M.D. (Photo: Business Wire) "Dr. Klopper is an exceptional addition to Veracyte's world-class medical team," said Dr. Kloos. "He was an investigator
Veracyte, Inc. (NASDAQ:VCYT), a global genomic diagnostics company, today announced the appointment of Rebecca Chambers as executive vice president and chief financial officer. Ms. Chambers, a seasoned financial executive with a track record for scaling high-growth healthcare businesses, will join the company July 19, reporting to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210712005237/en/Rebecca Chambers has been appointed EVP and Chief Financial Officer of Veracyte. (Photo: Business Wire) "We believe that our recent acquisitions and strategic initiatives have put in place th
Keith Kennedy will retire following Q1 earnings release and 10-Q; Jane Alley appointed as acting CFO; Veracyte to conduct CFO search Veracyte, Inc. (NASDAQ:VCYT) announced that Keith Kennedy, chief financial officer and chief operating officer, will retire from the company, effective May 15, 2021, following the company's release of its full quarterly financial results and the filing of its Form 10-Q for the first quarter 2021. Jane Alley, vice president and corporate controller, will become acting CFO until a replacement is named. Veracyte is conducting a search for a new CFO. "Keith has played a key role in Veracyte's growth and success over the last four years and the board and I deeply
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji, R.Ph., a global senior healthcare executive, to its board of directors, effective immediately. “We are thrilled to welcome Muna Bhanji to our board,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “She is a healthcare industry veteran with a distinguished career of driving successful commercialization and market access strategies across a range of products in global markets. Her guidance will be instrumental as we expand our global footprint with a growing menu of advanced genomic tests that impr
Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00
Goldman downgraded Veracyte from Buy to Neutral and set a new price target of $37.00 from $38.00 previously
Wolfe Research initiated coverage of Veracyte with a rating of Outperform and set a new price target of $50.00
UBS initiated coverage of Veracyte with a rating of Buy and set a new price target of $43.00
Guggenheim initiated coverage of Veracyte with a rating of Buy and set a new price target of $40.00
Needham reiterated coverage of Veracyte with a rating of Buy and set a new price target of $33.00 from $30.00 previously
Raymond James downgraded Veracyte from Outperform to Mkt Perform
Scotiabank initiated coverage of Veracyte with a rating of Sector Outperform and set a new price target of $33.00
Stephens & Co. reiterated coverage of Veracyte with a rating of Overweight and set a new price target of $44.00 from $52.00 previously
Raymond James reiterated coverage of Veracyte with a rating of Outperform and set a new price target of $34.00 from $62.00 previously